Abstract: Objective : To evaluate the efficacy and toxicity of two different regimens as salvage treatment in patients w ith anthracycline-resistant advanced breast cancer (ABC). Methods : 64 patients with anthracycline-resistant ABC were treated with docetaxel (DXL) (60mg/m² on day 1) plus cisplatin (DDP, 30mg/m² on days 1,2,3) or vinorelbine (NYB, 2smg/m², on days 1,8) plus cisplatin (30mg/m² on days 1,2,3) every 3 weeks. Analyses were by intention to treat. Results : In arm of D XL plus DDP, there were 2 complete (5.9%) and 16 partial responses (47%) among 34 patients for an overall response rate of 52.9%. The median time to progression was 8 months, the median survival time was 18 months, and the probability of 1-year survival was 62.9%. For 30 patients treated with NYB and DDP, the regimen produced an overall response rate of 43.3% (1CR, 12 PRs), a median time to progression of 7 months,and a median survival time of 15 months. The probability of 1-year survival was 54.8%. Grade 3-4 neutropenia was the main hematologic toxicity in both arms (48% vs.47%). The main non-hematologic toxicity was nausea/vomiting. Conclusion : Combinations of DXL w ith DDP and NYB with DDP are active salvage regimens for patients with anthracycline-resistant ABC, and the toxic effects were tolerable.There is no significant difference between objective responses of two regimens.